HTR1F
ENSG00000179097
Target class
GPCR
Chromosome
3
Approved drugs
7
Clinical candidates (approved and in development)
7
- Approved drugs
- 7
- Clinical candidates (approved and in development)
- 7
- Chemical probe available
- Yes
- Target name
- HTR1F
- Gene name
- 5-hydroxytryptamine receptor 1F
- Gene symbol
- HTR1F
- Protein name
- 5-hydroxytryptamine receptor 1F (5-HT-1F) (5-HT1F) (Serotonin receptor 1F)
- HTR1EL
- 5-HT1F
- Gene biotype
- Protein coding
- Gene family
- 5-hydroxytryptamine receptors, G protein-coupled
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 2
- Highest tissue expression
- 1.28
- Tissue specificity (Gini)
- 0.515
- Tissue specificity (tau)
- 0.811
- KEGG gene identifiers
- hsa:3355
- Protein interaction confidence
- 0.763647
- Protein interaction partners
- 17
- R-HSA-390666
- R-HSA-418594
- End position
- 87993839
- Start position
- 87792704
- Chromosome
- 3
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein .
- PubMed 21422162
- PubMed 8380639
- PubMed 8384716
- Tissue specificity (tau)
- 0.811468
- Expression inequality (Gini)
- 0.515004
Expression in transcripts per million
- Adipose - Subcutaneous
- 1.28
- Cervix - Ectocervix
- 1
- Cervix - Endocervix
- 0.89
- Breast - Mammary Tissue
- 0.73
- Pituitary
- 0.69
Expression in transcripts per million
- Adipose - Subcutaneous1.28
- Cervix - Ectocervix1
- Cervix - Endocervix0.89
- Breast - Mammary Tissue0.73
- Pituitary0.69
- Adipose - Visceral (Omentum)0.68
- Nerve - Tibial0.67
- Uterus0.66
- Thyroid0.51
- Lung0.46
- Fallopian Tube0.44
- Kidney - Medulla0.4
- Vagina0.35
- Testis0.35
- Brain - Frontal Cortex (BA9)0.3
- Cells - Cultured fibroblasts0.3
- Spleen0.28
- Brain - Cortex0.27
- Skin - Sun Exposed (Lower leg)0.25
- Prostate0.22
- Ovary0.22
- Brain - Anterior cingulate cortex (BA24)0.19
- Brain - Substantia nigra0.17
- Muscle - Skeletal0.15
- Brain - Amygdala0.15
And 29 more, listed on the interactive page.
- GO:0007187
- GO:0007193
- GO:0007198
- GO:0007268
Cellular components
- GO:0005886
- GO:0001586
- GO:0004993
- GO:0005515
- GO:0051378
Related records
Trials (1,268)
- "Extended" (Alternate Day) Antipsychotic Dosing
- "Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"
- [11C]Yohimbine PET Study of alpha2-AR
- 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain
- 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
- 28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years
- 3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)
- 3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)
- 40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)
- 5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia
- 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)
- 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)
- 9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)
- A 1-year Study in Adolescents to Assess the Long-term Safety of Almotriptan Malate When Treating Their Migraine Headaches
- A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
- A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers
- A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia
- A Clinical Study of the Safety and Efficacy of Chemogenetics Therapy in the Treatment of Parkinson's Disease
- A Clinical Trial of Lurasidone in Treatment of Schizophrenia
- A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Rolapitant and Palonosetron
Drugs (31)
- Almotriptan Serotonin 1f (5-HT1f) receptor agonist
- Almotriptan malate Serotonin 1f (5-HT1f) receptor agonist
- Amisulpride Serotonin (5-HT) receptor antagonist
- Clozapine
- Dexfenfluramine Serotonin (5-HT) receptor agonist
- Dexfenfluramine hydrochloride Serotonin (5-HT) receptor agonist
- Dihydroergotamine
- Donitriptan
- Eletriptan Serotonin 1f (5-HT1f) receptor agonist
- Eletriptan hydrobromide Serotonin 1f (5-HT1f) receptor agonist
- Ergotamine
- Lasmiditan Serotonin 1f (5-HT1f) receptor agonist
- Lasmiditan succinate Serotonin 1f (5-HT1f) receptor agonist
- Mebufotenin
- Metergoline
- Methylergonovine
- Methysergide
- Metitepine
- Naratriptan
- Olanzapine